Recombinant proteins are essential tools in biomedical research — serving as antigens for immunization, standards for ELISA, ligands for functional assays, and targets for drug screening. However, their biological activity and structural integrity depend heavily on how they are handled after arriving in your lab. Improper reconstitution, storage, or freeze-thaw cycling can denature proteins, destroy bioactivity, and waste both time and budget.
This guide covers everything you need to know to get the most out of your recombinant proteins — from the moment the package arrives to the final activity assay.
In This Guide
1. Receiving & Inspection
2. Reconstitution of Lyophilized Proteins
3. Storage & Aliquoting Best Practices
4. Carrier Proteins: When to Use and When to Avoid
5. Expression System Considerations
6. Verifying Protein Activity After Reconstitution
7. Frequently Asked Questions
1. Receiving & Inspection
When your recombinant protein arrives, follow these steps before opening the vial:
Check shipping conditions: Most lyophilized proteins ship at ambient temperature with ice packs. Liquid proteins should arrive on dry ice or cold packs. Verify the shipping temperature matches the product datasheet specifications.
Inspect the vial: Before opening, briefly centrifuge the vial (a few seconds at low speed) to collect all material at the bottom. Lyophilized protein appears as a white or off-white powder or pellet. Liquid protein should be clear; visible precipitate may indicate degradation or freeze-thaw damage during transit.
Read the datasheet first: Before reconstitution, review the Certificate of Analysis (COA) and product datasheet. Key information includes: recommended reconstitution buffer, stock concentration, storage conditions, carrier protein content (if any), and endotoxin level.
2. Reconstitution of Lyophilized Proteins
Lyophilization (freeze-drying) is the most common format for shipping recombinant proteins because it maximizes long-term stability. Proper reconstitution is critical to preserving bioactivity.
Step-by-Step Reconstitution
1. Briefly centrifuge the sealed vial to ensure all powder is at the bottom.
2. Add the recommended volume of sterile reconstitution buffer (typically sterile PBS, sterile water, or culture medium as specified on the datasheet). For a stock concentration of 0.1–1.0 mg/mL, this is usually 50–500 µL depending on the protein quantity.
3. Add the buffer slowly down the side of the vial — do not pipette directly onto the pellet, as this can cause foaming and protein loss.
4. Allow the protein to dissolve by gentle rotation or swirling for 10–30 minutes at room temperature. Do not vortex vigorously — mechanical shearing can denature proteins, especially large multidomain proteins and cytokines.
5. Once fully dissolved, the solution should be clear. If slight turbidity persists, allow additional time at room temperature or gently pipette up and down (avoid bubbles). Persistent cloudiness may indicate incomplete reconstitution or aggregation.
Reconstitution buffer choice: When the datasheet says "sterile water," this typically means deionized, endotoxin-free water. For proteins that tend to aggregate at low ionic strength, adding a small amount of carrier protein (0.1% BSA) or using PBS instead of pure water can improve stability. For in vivo applications, always use endotoxin-free buffers and verify the endotoxin level on the COA.
| Reconstitution Scenario |
Recommended Buffer |
| General research (ELISA, WB, cell culture) |
Sterile PBS or sterile deionized water, per datasheet |
| Proteins prone to aggregation |
PBS + 0.1% BSA as carrier; or 20 mM Tris pH 8.0 + 150 mM NaCl |
| Cell-based functional assays (bioactivity) |
Sterile cell culture medium or sterile PBS + 0.1% BSA |
| In vivo animal studies |
Endotoxin-free PBS or saline; use carrier-free (CF) protein; verify endotoxin < 1 EU/µg |
| Immunization / antibody generation |
Sterile PBS (carrier-free preferred to avoid anti-BSA antibody responses) |
3. Storage & Aliquoting Best Practices
Repeated freeze-thaw cycles are the single biggest threat to recombinant protein integrity. Each cycle promotes ice crystal formation, concentration gradients at the air-liquid interface, and oxidative damage — all leading to irreversible aggregation and activity loss.
| Format |
Short-Term (< 1 week) |
Long-Term |
| Lyophilized (unopened) |
4°C |
−20°C to −80°C (up to 12 months) |
| Reconstituted / liquid |
4°C (use within 5–7 days) |
−20°C to −80°C in single-use aliquots |
Aliquoting Protocol
1. Immediately after reconstitution, divide the stock into single-use aliquots in sterile, low-protein-binding microcentrifuge tubes (polypropylene or siliconized).
2. Aliquot volumes should match your typical single-experiment needs (e.g., 10–50 µL each). This eliminates the need to thaw and re-freeze the same tube.
3. Snap-freeze aliquots in liquid nitrogen or a dry ice/ethanol bath for rapid freezing. Slow freezing (simply placing tubes in −20°C) promotes ice crystal formation.
4. Store at −20°C (for up to 3 months) or −80°C (for 6–12 months). Label each tube with protein name, lot number, concentration, date, and aliquot volume.
Critical rule: Never exceed 3 freeze-thaw cycles for any recombinant protein. Most manufacturers recommend a maximum of 2 cycles. If you need to use a protein repeatedly over several days, keep a working aliquot at 4°C and discard after one week.
4. Carrier Proteins: When to Use and When to Avoid
Many recombinant proteins are supplied with a carrier protein (typically BSA at 0.1%) to improve stability during storage and reduce non-specific adsorption to tube walls. While carrier proteins are beneficial for most in vitro applications, they are problematic in specific contexts.
| Application |
Use Carrier (+ BSA)? |
Rationale |
| ELISA standard curves |
Yes |
BSA stabilizes dilute protein solutions and prevents adsorption losses |
| Cell stimulation / bioactivity assays |
Yes (usually acceptable) |
BSA at 0.1% does not interfere with most cell-based assays |
| Animal immunization |
Avoid |
BSA is immunogenic and will generate anti-BSA antibodies that contaminate the immune response |
| In vivo studies |
Avoid |
Exogenous BSA may cause immune reactions in animals; use carrier-free (CF) formulations |
| Mass spectrometry |
Avoid |
BSA peptides dominate MS spectra and mask target protein signals |
| ELISA plate coating antigen |
Avoid |
BSA competes for binding sites on the plate surface, reducing coating efficiency |
Tip: When ordering, check whether the protein is supplied as "carrier-free" (CF) or "with BSA." Many abinScience proteins are available in both formats. If you need the same protein for both ELISA standards (BSA acceptable) and immunization (BSA-free required), order the carrier-free version and add BSA yourself where needed.
5. Expression System Considerations
The expression system used to produce a recombinant protein affects its folding, post-translational modifications (PTMs), and biological activity. Choosing the right expression system for your application can make the difference between functional and non-functional protein.
| Expression System |
PTMs |
Best For |
Limitations |
| E. coli |
None (no glycosylation) |
ELISA antigens, immunogens, structural studies, cost-sensitive applications |
No mammalian PTMs; may require refolding; endotoxin contamination risk |
| Mammalian cells (HEK293, CHO) |
Full (glycosylation, disulfide bonds, correct folding) |
Functional/bioactivity assays, cell-based studies, in vivo research, receptor-ligand binding |
Higher cost; lower yield for some targets |
| Insect cells (Sf9, Hi5) |
Partial (simple glycosylation) |
Structural studies, vaccine antigens, membrane proteins |
Non-mammalian glycosylation patterns |
| Yeast (Pichia, S. cerevisiae) |
Some glycosylation (high-mannose) |
Secreted proteins, cost-effective scale-up |
Hyperglycosylation can affect antigenicity |
Quick decision: Need the protein as an ELISA standard or immunogen? E. coli-expressed is typically sufficient and more affordable. Need native-like bioactivity for cell stimulation, receptor binding, or in vivo studies? Choose mammalian-expressed protein to ensure correct folding and glycosylation.
6. Verifying Protein Activity After Reconstitution
Always verify that your reconstituted protein retains expected activity before using it in a critical experiment. Common verification methods include:
| Method |
What It Tests |
When to Use |
| SDS-PAGE |
Purity, molecular weight, degradation |
Routine QC — confirms the protein is intact and not degraded |
| ELISA (as antigen) |
Epitope accessibility, antibody binding |
Coat the protein on an ELISA plate and detect with a known antibody — confirms epitope integrity |
| Cell-based bioassay |
Functional activity (e.g., cytokine-induced proliferation, receptor activation) |
Essential for cytokines and growth factors used in cell stimulation |
| SPR / BLI |
Binding kinetics (KD, kon, koff) |
Critical for drug development and antibody characterization applications |
7. Frequently Asked Questions
Q: My reconstituted protein has visible precipitate. Is it still usable?
Slight turbidity immediately after reconstitution may resolve with gentle swirling and additional time at room temperature. However, persistent precipitate after 30 minutes typically indicates protein aggregation. This can be caused by reconstituting at too high a concentration, using the wrong buffer, or excessive freeze-thaw. Try reconstituting a fresh vial at a lower concentration or in a buffer with higher ionic strength. If the datasheet specifies a maximum recommended concentration, do not exceed it.
Q: Can I add glycerol to my protein aliquots for storage?
Yes, adding glycerol to a final concentration of 5–50% (depending on the protein) can act as a cryoprotectant and prevent ice crystal formation during freezing. Glycerol-containing aliquots stored at −20°C remain liquid, allowing pipetting without full thawing — which is convenient for proteins used repeatedly. However, glycerol may interfere with certain downstream applications (e.g., mass spectrometry, some cell-based assays). Always check compatibility before adding glycerol.
Q: Does the expression system matter for ELISA standards?
For sandwich ELISA, the expression system matters less as long as the protein retains the epitopes recognized by both the capture and detection antibodies. E. coli-expressed proteins work well for most ELISA standard curves and are more cost-effective. However, if your ELISA antibodies were raised against the glycosylated form of the protein, an E. coli-expressed (non-glycosylated) standard may not be recognized. In that case, use a mammalian-expressed standard.
Q: How many freeze-thaw cycles can I do before the protein loses activity?
This varies by protein, but as a general rule: assume activity loss begins after 2–3 freeze-thaw cycles. Some robust proteins (e.g., BSA, streptavidin) tolerate 5+ cycles, while sensitive cytokines and growth factors can lose significant activity after a single cycle. The only way to know for sure is to test activity after each cycle. The best strategy is to prevent the problem entirely by aliquoting into single-use volumes immediately after reconstitution.
Q: What is the difference between "tag" and "native" recombinant proteins?
Most recombinant proteins carry a fusion tag (His-tag, Fc-tag, GST-tag, etc.) that aids purification. Tags are usually small and do not affect function for most applications. However, for structural studies, crystallography, or assays where the tag may interfere with binding (e.g., Fc-tagged proteins in Fc receptor assays), tag-free or native-sequence proteins are preferred. Some manufacturers offer both tagged and untagged versions of the same protein.
Browse Recombinant Proteins at abinScience
abinScience offers over 13,500 recombinant proteins across human, mouse, rat, and pathogen species. Expression systems include E. coli (~11,200), mammalian HEK293/CHO (~2,100), and insect cells (~100). Available with or without carrier protein, with COA and endotoxin data included.
Explore Recombinant Proteins →
References
1. Rosano GL, Ceccarelli EA. Recombinant protein expression in Escherichia coli: advances and challenges. Front Microbiol. 2014;5:172. doi: 10.3389/fmicb.2014.00172
2. Dumont J, Euwart D, Mei B, Estes S, Kshirsagar R. Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives. Crit Rev Biotechnol. 2016;36(6):1110-1122. doi: 10.3109/07388551.2015.1084266
3. Wingfield PT. Overview of the purification of recombinant proteins. Curr Protoc Protein Sci. 2015;80:6.1.1-6.1.35. doi: 10.1002/0471140864.ps0601s80
From Protein to Antibody to Kit
abinScience's full target chain: recombinant proteins, matched antibodies, and ELISA kits — all from one manufacturer.
Shop by Target →
This article is provided for educational purposes only. Protocols should be optimized for each specific application. For technical support, contact order@abinscience.com.
中文
English
한국어
日本語
Español
Français
Русский
